Longeveron, a biotechnology company focused on developing cellular therapies, has been named a semifinalist and one of the Top 40 teams in the XPRIZE Healthspan competition. The company was selected based on the feasibility and promise of its stem cell therapy, laromestorcel, which is currently under evaluation as a potential treatment for Alzheimer’s disease and hypoplastic left heart syndrome (HLHS), a rare and life-threatening congenital heart defect in children. As part of this recognition, Longeveron will receive a $250,000 Milestone 1 Award. The XPRIZE Healthspan competition is an international contest aimed at accelerating innovations that can extend healthy human lifespan. Longeveron's inclusion as a semifinalist highlights the growing interest in regenerative medicine and the potential for stem cell therapies to address both common and rare diseases. The company’s research into laromestorcel is ongoing, with clinical trials assessing its safety and efficacy in both Alzheimer’s patients and children with HLHS. The award provides additional funding and validation for Longeveron's approach, potentially advancing the development of new treatments for these challenging conditions.